Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced its contribution to new research leveraging Multiplexed Assays ...

We had a great 2025, laying a solid foundation to execute our strategy, become the trusted network for AI. The impact of the deal on our capital structure and financials is very significant. All of ...

A JoongAng Ilbo reporter slid into the driver’s seat of Renault Korea’s new car, the Filante, and decided to skip the ...